Back to results
US 2019/0194293 A1Published application
Soluble interferon receptors and uses thereof
AssigneeSanabio, LLC
InventorsJames Arthur POSADA, Pamela SMOLAK
Life of this patent
Estimating the term…
Abstract
The present disclosure provides soluble interferon receptors. The methods of the disclosure can be used to treat or prevent a condition associated with an abnormal immune response.
Claims45
A heterodimer which binds type I interferons comprising a first polypeptide and a second polypeptide, wherein the first polypeptide comprises an interferon receptor 1 (IFNAR1) domain operatively coupled with or without a linker domain to a mutant Fc domain, and wherein the second polypeptide comprises an interferon receptor 2 (IFNAR2) domain operatively coupled with or without a linker domain to a mutant Fc domain.
3-4. (canceled)
(canceled)
(canceled)
14-16. (canceled)
(canceled)
22-26. (canceled)
28-32. (canceled)
36-37. (canceled)
40-43. (canceled)
A heterodimer which binds type I interferons comprising a first polypeptide and a second polypeptide, wherein
- (a) the first polypeptide comprises an IFNAR1 domain operatively coupled to a mutant IgG1 Fc domain comprising mutations T350V, T366L, K392L and T394W, and wherein the second polypeptide comprises an IFNAR2 domain operatively coupled to a mutant IgG1 Fc domain comprising mutations T350V, L351Y, F405A and Y407V, according to EU numbering;
- or
- (b) the first polypeptide comprises an IFNAR1 domain operatively coupled to a mutant IgG1 Fc domain comprising mutations T350V, L351Y, F405A and Y407V, and wherein the second polypeptide comprises an IFNAR2 domain operatively coupled to a mutant IgG1 Fc domain comprising mutations T350V, T366L, K392L and T394W, according to EU numbering.
45-58. (canceled)
60-63. (canceled)
A heterodimer which binds type I interferons comprising a first polypeptide and a second polypeptide selected from:
- (i) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 40 and a second polypeptide comprising the amino acid sequence of SEQ ID NO:
- 43;
- (ii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 41 and a second polypeptide comprising the amino acid sequence of SEQ ID NO:
- 42;
- (iii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 53 and a second polypeptide comprising the amino acid sequence of SEQ ID NO:
- 55;
- and
- (iv) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 57 and a second polypeptide comprising the amino acid sequence of SEQ ID NO:
- 59;
- (v) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 40, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 43, SEQ ID NO:
- 55, and SEQ ID NO:
- 59;
- (vi) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 43, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 40, SEQ ID NO:
- 53, and SEQ ID NO:
- 57;
- (vii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 42, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 41, SEQ ID NO:
- 45, and SEQ ID NO:
- 47;
- (viii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 41, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 42, SEQ ID NO:
- 49, and SEQ ID NO:
- 51;
- (ix) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 53, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 43, SEQ ID NO:
- 55, and SEQ ID NO:
- 59;
- (x) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 55, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 40, SEQ ID NO:
- 53, and SEQ ID NO:
- 57;
- (xi) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 57, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 43, SEQ ID NO:
- 55, and SEQ ID NO:
- 59;
- (xii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 59, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 40, SEQ ID NO:
- 53, and SEQ ID NO:
- 57;
- (xiii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 45, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 42, SEQ ID NO:
- 49, and SEQ ID NO:
- 51;
- (xiv) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 47, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 42, SEQ ID NO:
- 49, and SEQ ID NO:
- 51;
- (xv) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 49, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 41, SEQ ID NO:
- 45, and SEQ ID NO:
- 47;
- (xvi) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 51, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 41, SEQ ID NO:
- 45, and SEQ ID NO:
- 47;
- (xvii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 61, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 67, SEQ ID NO:
- 75, and SEQ ID NO:
- 82;
- (xviii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 63, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 65, SEQ ID NO:
- 73, and SEQ ID NO:
- 81;
- (xix) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 65, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 63, SEQ ID NO:
- 71, and SEQ ID NO:
- 79;
- (xx) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 67, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 61, SEQ ID NO:
- 69, and SEQ ID NO:
- 77;
- (xxi) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 69, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 67, SEQ ID NO:
- 75, and SEQ ID NO:
- 82;
- (xxii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 71, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 65, SEQ ID NO:
- 73, and SEQ ID NO:
- 81;
- (xxiii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 73, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 63, SEQ ID NO:
- 71, and SEQ ID NO:
- 79;
- (xxiv) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 75, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 61, SEQ ID NO:
- 69, and SEQ ID NO:
- 77;
- (xxv) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 77, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 67, SEQ ID NO:
- 75, and SEQ ID NO:
- 82;
- (xxvi) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 79, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 65, SEQ ID NO:
- 73, and SEQ ID NO:
- 81;
- (xxvii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 81, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 63, SEQ ID NO:
- 71, and SEQ ID NO:
- 79;
- (xxviii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 82, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 61, SEQ ID NO:
- 69, and SEQ ID NO:
- 77;
- (xxix) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 84, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 89, SEQ ID NO:
- 97, and SEQ ID NO:
- 105;
- (xxx) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 85, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 87, SEQ ID NO:
- 95, and SEQ ID NO:
- 103;
- (xxxi) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 87, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 85, SEQ ID NO:
- 93, and SEQ ID NO:
- 101;
- (xxxii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 89, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 84, SEQ ID NO:
- 91, and SEQ ID NO:
- 99;
- (xxxiii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 91, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 89, SEQ ID NO:
- 97, and SEQ ID NO:
- 105;
- (xxxiv) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 93, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 87, SEQ ID NO:
- 95, and SEQ ID NO:
- 103;
- (xxxv) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 95, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 85, SEQ ID NO:
- 93, and SEQ ID NO:
- 101;
- (xxxvi) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 97, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 84, SEQ ID NO:
- 91, and SEQ ID NO:
- 99;
- (xxxvii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 99, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 89, SEQ ID NO:
- 97, and SEQ ID NO:
- 105;
- (xxxviii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 101, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 87, SEQ ID NO:
- 95, and SEQ ID NO:
- 103;
- (xxxix) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 103, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 85, SEQ ID NO:
- 93, and SEQ ID NO:
- 101;
- and
- (xl) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
- 105, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
- 84, SEQ ID NO:
- 91, and SEQ ID NO:
- 99.
191 more elements
65-74. (canceled)
82-85. (canceled)
87-89. (canceled)
Dependencies are inferred from the claim text.